Takeda Pharmaceutical Company Limited and Taro Pharmaceutical Industries Ltd.: SG&A Spending Patterns Compared

Takeda vs. Taro: SG&A Spending Trends Unveiled

__timestampTakeda Pharmaceutical Company LimitedTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201461261300000091733000
Thursday, January 1, 201565077300000087644000
Friday, January 1, 201661906100000092365000
Sunday, January 1, 201762810600000085656000
Monday, January 1, 201871759900000088196000
Tuesday, January 1, 201996473700000089971000
Wednesday, January 1, 202087566300000093413000
Friday, January 1, 202188636100000091355000
Saturday, January 1, 2022997309000000113676000
Sunday, January 1, 20231053819000000198366000
Monday, January 1, 20241053819000000218935000
Loading chart...

Data in motion

SG&A Spending Patterns: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, understanding spending patterns is crucial. Takeda Pharmaceutical Company Limited, a Japanese multinational, and Taro Pharmaceutical Industries Ltd., an Israeli company, offer a fascinating study in contrasts. Over the past decade, Takeda's Selling, General, and Administrative (SG&A) expenses have surged by approximately 72%, reflecting its aggressive expansion and strategic acquisitions. In 2023, Takeda's SG&A expenses reached a staggering 1.05 trillion yen, a testament to its global ambitions.

Conversely, Taro's SG&A expenses have remained relatively stable, with a modest increase of around 140% since 2014. This stability highlights Taro's focus on maintaining operational efficiency while navigating the complex pharmaceutical landscape. As we look to the future, these spending patterns may offer insights into each company's strategic priorities and market positioning.

A Decade of Divergent Strategies

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025